ENLV
Enlivex Therapeutics Ltd
NASDAQ: ENLV · HEALTHCARE · BIOTECHNOLOGY
$0.82
-0.46% today
Updated 2026-05-01
Market cap
$197.61M
P/E ratio
0.03
P/S ratio
—
EPS (TTM)
$25.48
Dividend yield
—
52W range
$1 – $2
Volume
0.6M
Enlivex Therapeutics Ltd (ENLV) Financial Forecast & Price Target 2030
Revenue-driven projection model with historical context.
Price target summary
Current price
$0.82
12-Month target
$1.02
2030 Target
—
Intrinsic (DCF)
—
Financial forecast
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $0.0B | $0.0B | $0.0B | $0.0B | $0.0B |
| EPS | — | — | — | — | — |
CAGR applied: — (capped 20%) · P/E: 0.03x (capped 25x) · Margin: 0.00%
Methodology
CAGR-based projection model. Research-backed estimates are being generated — check back soon for analyst consensus and management guidance.